Latest News

See All News

RxBio CEO Dr. W. Shannon McCool is Featured on the "CEO Money" (Segments 2 & 3) Program Airing August 22, 2017, on World Finance News 1.

SBIR (NIH) Funds RxBio Work Assessing the Anti-Diarrheal Potential of an LPA analog Rx100

SBIR (NIH) Funds Continued Development of RxBio's Rx100 as a Novel Medical Countermeasure for Acute Radiation Syndrome.

Combined Mitigation of the Gastrointestinal and Hematopoietic Acute Radiation Syndromes by an LPA2 Receptor-Specific Nonlipid Agonist. See abstract on cell.com

Milestones

 

More News

NIAID Funds RxBio's Development of Medical Countermeasures to Mitigate or Treat the GI-ARS after a Nuclear or Radiation Incident.

NIAID Funds Tigyi (UTHSC) Work for IND-Enabling Preclinical Development of a New RxBio Radiomitigator

McCool, RxBio Holdings team pursuing a second promising drug. Read more...

RxBio’s Shannon McCool following a non-traditional commercialization path. Read more...